Crossmark

Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Crossref DOI link: https://doi.org/10.1007/s12325-022-02402-z

Published Online: 2023-01-09

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fang, Rui

Wang, Suiqiong

Liu, Yongqian

Xu, Jun
Funding

Funding for this research was provided by:

Guangdong Medical Research Foundation (2022A35)

Guangdong Provincial Key Laboratory for Translational Cancer Research of Chinese Medicine, Guangzhou University of Chinese Medicine (2021YXQN10)
License Information

Text and Data Mining valid from 2023-01-09

Version of Record valid from 2023-01-09
More Information

Article History

Received: 10 October 2022

Accepted: 25 November 2022

First Online: 9 January 2023

Document is current

Any future updates will be listed below